Related Experiment Video
Updated: Aug 29, 2026

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host
Published on: July 27, 2010
Visceral leishmaniasis treatment, Italy
Luigi Gradoni1, Marina Gramiccia, Aldo Scalone
1Laboratorio di Parassitologia, Istituto Superiore di Sanità, Rome, Italy. gradoni@iss.it
First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change in therapy is a response to both disease reemergence and increasing antimonial failure.
First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change in therapy is a response to both disease reemergence and increasing antimonial failure.
Related Concept Videos
Leishmaniasis
Antiprotozoal Agents
American Trypanosomiasis
Trichomoniasis

